{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:12Z","timestamp":1787237952721,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T00:00:00Z","timestamp":1039564800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Apheresis"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:<\/jats:bold>\n                    The effectiveness of plasma exchange (PE) with continuous hemodiafiltration (CHDF) in the treatment of critically ill patients was evaluated based on changes in cytokine levels. Twenty\u2010six patients with acute hepatic failure were treated with PE (PE group) or PE and CHDF (PE+CHDF group), and the levels of cytokines such as tumor necrosis factor (TNF)\u2010\u03b1, interleukin (IL)\u20106, and IL\u20108 were determined before and after treatment. Bilirubin levels were significantly lower after treatment in both the PE and PE+CHDF groups. There were no significant differences in TNF\u2010\u03b1 levels before and after treatment in the PE group, but the TNF\u2010\u03b1 level was significantly lower after treatment in the PE+CHDF group. There were no significant differences in the IL\u20106 levels before and after treatment in both the PE and PE+CHDF groups. There were no significant differences in IL\u20108 levels before and after treatment in the PE group, but the IL\u20108 level was significantly lower after treatment in the PE+CHDF group. PE with CHDF therapy was given to 5 patients with acutely aggravated autoimmune diseases, 2 patients with hemorrhagic shock and encephalopathy syndrome, and 3 patients with thrombotic microangiopathy. The results suggested that PE with CHDF therapy are useful in critically ill patients with suspected hypercytokinemia.\n                  <\/jats:p>","DOI":"10.1046\/j.1526-0968.2002.00464.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T16:02:19Z","timestamp":1047484939000},"page":"419-424","source":"Crossref","is-referenced-by-count":51,"title":["Cytokine Removal by Plasma Exchange with Continuous Hemodiafiltration in Critically Ill\u2003Patients"],"prefix":"10.1111","volume":"6","author":[{"given":"Hajime","family":"Nakae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Tajimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,12,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342207"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705013361807"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0600031154.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709516"},{"key":"e_1_2_6_6_2","first-page":"65","article-title":"Are proinflammatory cytokine concentrations reduced by plasma exchange in patients with severe acute hepatic failure?","volume":"109","author":"Nakae H","year":"2001","journal-title":"Res Commun Molec Pathol Pharmacol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2001.00380.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","unstructured":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med1992;20:864\u201374.","DOI":"10.1097\/00003246-199206000-00025"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80783-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.206"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1989.29289146829.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80349-6"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00143.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726541"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.47"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02482322"},{"key":"e_1_2_6_17_2","first-page":"92","article-title":"Changes in the serum levels of inflammatory cytokines following CHDF for severe acute pancreatitis: a report of five cases.","volume":"2","author":"Nakae H","year":"2001","journal-title":"Crit Care Shock"},{"key":"e_1_2_6_18_2","first-page":"99","article-title":"Removal of interleukin\u20101 beta and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes.","volume":"11","author":"Barrera P","year":"1992","journal-title":"Lymphokine Cytokine Res"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/378088a0"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.159.8.3961","article-title":"IL\u201018 accounts for both TNF\u2010\u03b1\u2010 and Fas ligand\u2010mediated hepatotoxic pathways in endotoxin\u2010induced liver injury in mice.","volume":"159","author":"Tsutsui H","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/jcrc.2001.25470"},{"key":"e_1_2_6_22_2","first-page":"35","article-title":"Plasma exchange and continuous hemodiafiltration as an initial treatment for diffuse large B\u2010cell lymphoma\u2010associated hemophagocytic syndrome.","volume":"43","author":"Yanagiya N","year":"2002","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1998.tb00127.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.1999.00209.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80917-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00647296"}],"container-title":["Therapeutic Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-0968.2002.00464.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2002.00464.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1526-0968.2002.00464.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2002.00464.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:05:40Z","timestamp":1694333140000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-0968.2002.00464.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1046\/j.1526-0968.2002.00464.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-0968.2002.00464.x","archive":["Portico"],"relation":{},"ISSN":["1091-6660","1526-0968"],"issn-type":[{"value":"1091-6660","type":"print"},{"value":"1526-0968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}